ReviewDrug discovery today2020
The quest for the holy grail: new antitubercular chemical entities, targets and strategies.
Review in Drug discovery today, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- Exploring the Potential of Coumarin as a Potent Antitubercular Agent.Mini reviews in medicinal chemistry · 2026Review
- Unlocking potent anti-tuberculosis natural products through structure-activity relationship analysis.Natural products and bioprospecting · 2025Review
- Nanoenabling MbtI Inhibitors for Next-Generation Tuberculosis Therapy.Journal of medicinal chemistry · 2025Article
- Advancing the fight against tuberculosis: integrating innovation and public health in diagnosis, treatment, vaccine development, and implementation science.Frontiers in medicine · 2025Review
- Discovery of anti-infective compounds againstFrontiers in microbiology · 2024Article
- The progress ofFrontiers in medicine · 2024Review
- Pathogenicity and virulence ofVirulence · 2023Review
- Tuberculosis diagnostic and treatment delays among patients in Uganda.Health science reports · 2023Article
- Review
- Target Identification in Anti-Tuberculosis Drug Discovery.International journal of molecular sciences · 2023Review
- The implication of Mycobacterium tuberculosis-mediated metabolism of targeted xenobiotics.Nature reviews. Chemistry · 2023Review
- Recent developments of imidazo[1,2-RSC medicinal chemistry · 2023Review
- Nitrobenzoates and Nitrothiobenzoates with Activity againstMicroorganisms · 2023Article
- Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets.International journal of molecular sciences · 2023Review
- Synthesis and characterization of different complexes derived from Schiff base and evaluation as a potential anticancer, antimicrobial, and insecticide agent.Saudi journal of biological sciences · 2023Article
- Machine Learning Prediction of Mycobacterial Cell Wall Permeability of Drugs and Drug-like Compounds.Molecules (Basel, Switzerland) · 2023Article
- Recent Advances of DprE1 Inhibitors againstACS omega · 2022Review
- 1,3-Diarylpyrazolyl-acylsulfonamides Target HadAB/BC Complex inACS infectious diseases · 2022Article
- Identification of hydantoin based Decaprenylphosphoryl-β-D-Ribose Oxidase (DprE1) inhibitors as antimycobacterial agents using computational tools.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) remains the leading cause of death from an infectious disease worldwide. TB therapy is complicated by the protracted treatment regimens, development of resistance coupled with toxicity and insufficient sterilizing capacity of current drugs. Although considerable progress has been made on establishing a TB drug pipeline, the high attrition rate reinforces the need to continually replenish the pipeline with high-quality leads that act through inhibition of novel targets. In this review, we highlight some of the key advances that have assisted TB drug discovery with novel chemical matter, targets and strategies - to fuel the TB drug pipeline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.